12 Sept 2024
Novo Nordisk's new obesity pill, amycretin, has shown promising results in early clinical trials, with participants losing up to 13% of their body weight in just 12 weeks, significantly outperforming placebo groups. The treatment may offer faster weight loss than Novo's popular Wegovy injection.
New research identifies rare genes behind early menopause
13 Sept 2024
Night owls more likely to develop type 2 diabetes
12 Sept 2024
New weight loss pill outperforms Wegovy in early trials
12 Sept 2024